Coty vs Revolution Beauty

8-K Financial Filing Analysis for Coty (2026-09-11)

Coty Inc. reported formal leadership transition terms for outgoing Chief Financial Officer Laurent Mercier following the appointment of Soraya Benchikh as CFO. Mercier stepped down as CFO on September 1, 2026, transitioning to a Strategic CEO Advisor role through June 30, 2027. Under the Transition Agreement, Mercier will maintain an annual base salary of €825,000, actively assisting with handoff duties through October 2026 before being released from active responsibilities on November 1, 2026. The agreement specifies an optional early exit acceleration starting December 20, 2026, a fixed one-time bonus of €290,000 in lieu of standard FY2026/FY2027 variable compensation, continued vesting of October 2026 equity tranches, and standard post-employment non-compete terms.

• Laurent Mercier stepped down as CFO on September 1, 2026, serving as Strategic CEO Advisor through June 30, 2027, with full duties ending October 31, 2026.
• Mercier will continue to receive an annual base salary of €825,000 and a one-time fixed bonus of €290,000, while forfeiting variable bonuses for FY2026 and FY2027.
• The Transition End Date can be accelerated at Mercier's option to no earlier than December 20, 2026, with equity scheduled to vest in October 2026 remaining eligible to vest.

Coty Strengthens U.S. Consumer Beauty Leadership with Key Appointments

Coty Inc. announced the appointment of Kara Langan as General Manager, Consumer Beauty U.S., marking a significant step in strengthening the company's Consumer Beauty leadership team and accelerating growth in one of its most important markets.

Coty Strengthens U.S. Consumer Beauty Leadership with Key Appointments

Coty Inc. today announced the appointment of Kara Langan as General Manager, Consumer Beauty U.S., marking another significant step in strengthening the company's Consumer Beauty leadership team and accelerating growth in one of its most important markets.

8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)

On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.

• CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
• Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
• Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.